UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
BGLC holding history
BioNexus Gene Lab Corp in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BGLC overviewAll 13F holders of BGLCFull Q2 2026 holdings
- Shares (Q2 2026)
- 101
- Value
- $197
- % of portfolio
- <0.1%
- Quarters held
- 8
- Since Q1 2024
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | $197 | <0.1% | −130−56.3% | Reduced | Holders |
| Q1 2026 | 231 | $495 | <0.1% | +231 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −7,626−100.0% | Sold out | Holders |
| Q3 2025 | 7,626 | $41.7K | <0.1% | −1,936−20.2% | Reduced | Holders |
| Q2 2025 | 9,562 | $29.4K | <0.1% | +9,558+238,950.0% | Added | Holders |
| Q1 2025 | 4 | $1 | <0.1% | −109,628−100.0% | Reduced | Holders |
| Q4 2024 | 109,632 | $30.7K | <0.1% | +26,324+31.6% | Added | Holders |
| Q3 2024 | 83,308 | $37.1K | <0.1% | +83,308 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −8,418−100.0% | Sold out | Holders |
| Q1 2024 | 8,418 | $5.94K | <0.1% | +8,418 | New | Holders |